Intra-articular Corticosteroid With Hyaluronic Acid Plus Physiotherapy for Hip Pathologies
Hip pathologies that cause pain and functional limitations are common in the general population. These can include femoroacetabular impingement (FAI), labral tears and mild osteoarthritis (OA) among others. While more severe and symptomatic cases may require surgical intervention, the treatment of mild-to-moderate case
| Condition(s) | Osteoarthritis, Femoroacetabular Impingement Syndrome, Labrum Injury of the Hip Joint |
|---|---|
| Status | Recruiting |
| Phase | NA |
| Study type | Interventional |
| Summary | Hip pathologies that cause pain and functional limitations are common in the general population. These can include femoroacetabular impingement (FAI), labral tears and mild osteoarthritis (OA) among others. While more severe and symptomatic cases may require surgical intervention, the treatment of mild-to-moderate cases is often treated without surgery to relieve pain, improve function, and delay surgical intervention. Non-operative treatments of hip pathologies consist of a multitude of options. A common non-operative intervention includes intra-articular injections, including corticosteroids and hyaluronic acid. Evidence has demonstrated that corticosteroids have fast acting effects which tend to diminish within a few months, while hyaluronic acid has a delayed time of onset and demonstr |
| Who can participate | Inclusion Criteria: 1. Patients aged 40-60 years old. 2. Patients with mild hip arthritis (Kellgren-Lawrence grade 2 or lower) with or without a labral tear and/or femoroacetabular impingement and/or mild hip dysplasia. 3. Patients who demonstrate more than 50% reduction in hip pain following a diagnostic injection (ultrasound guided intra-articular anaesthetic only). 4. Able to subsidize private physiotherapy services. 5. Able to provide informed consent. Exclusion Criteria: 1. Active infection 2. Osteonecrosis of the hip, moderate to severe arthritis (Kellgren-Lawrence grade 3 or higher), or moderate-to-severe hip dysplasia 3. Previous hip fracture, pelvic fracture, or lower limb fracture, 4. Previous surgery to the pelvis, hip or lower limb 5. Hypermobility disorder or connective tissue |
| Ages | 40 Years to 60 Years |
| Sex | All |
| Lead sponsor | ArthroBiologix Inc. |
| Locations | Hamilton, Ontario, Canada |
| Start date | 2024-05-01 |
| NCT ID | NCT06653985 |
| Official listing | https://clinicaltrials.gov/study/NCT06653985 |